BackgroundAlthough cervix carcinoma is one of the most common malignancies in women, hematogenous metastases are relatively not common. Cutaneous metastases, in particular, are unusual even at an advanced stage of disease. Their presence is a predictor of poor prognosis.Case presentationCase 1: A 63-year-old postmenopausal Moroccan woman was diagnosed as having cervical squamous cell carcinoma. She was treated with radical concurrent chemotherapy and radiation therapy followed by low-dose brachytherapy. Six months after finishing the therapy, multiple skin nodules appeared on her abdomen and chest wall. An excision biopsy was performed and showed metastatic squamous cell carcinoma. Her disease progressed and she died before completing her fourth course of palliative chemotherapy.Case 2: A 48-year-old Moroccan woman was diagnosed as having cervical squamous cell carcinoma; she was treated with concurrent chemoradiation. Before a planned high-dose brachytherapy, she noticed many nodular lesions on her arms, thighs, and chest wall. An excision biopsy was performed and showed metastatic squamous cell carcinoma. She then underwent a series of imaging examinations, including computed tomography of her chest, abdomen, and pelvis, and a whole body bone scan that showed disseminated disease involving her lungs and bones. She died after two courses of palliative chemotherapy, 2 months after the appearance of the skin lesions.ConclusionWe report two cases to illustrate a rare localization of metastasis from cervical carcinoma that is highly aggressive requiring early detection and aggressive management.

Radiation induced Lumbosacral plexophaty (RILP) is a rare but severe complication that has a considerable impact on quality of life. Its occurrence is rare but increasing with improved long-term cancer survival. This entity commonly results in different degrees of sensory and motor deficits. The pathophysiological mechanisms are not yet fully understood. Diagnosis of radiation myelopathy in women with gynecologic malignancies may increase with the use of concomitant chemo-radiation. This report describes the effect of this combination therapy in a 64-year-old woman with cervical carcinoma.

No abstract

Le gliosarcome est une tumeur cérébrale très rare représentant 1,8 à 8% de l’ensemble des tumeurs gliales. Il est considéré par l’organisation mondiale de la santé comme une variante de glioblastome. C’est une tumeur à double composante gliale et sarcomateuse. Le tableau clinique est polymorphe, les données de l’imagerie sont évocatrices, la confirmation est histologique. Le traitement est essentiellement chirurgical. Le pronostic est lié étroitement à la qualité d’exérèse. Dans notre travail Nous rapportons deux observations cliniques dont l’objectif est de faire le point sur les particularités, essentiellement diagnostiques, thérapeutiques ainsi que pronostiques de cette entité rare.

5 à 10% des patients atteints de neurofibromatose de type 1 (NF1) développent des tumeurs malignes des gaines des nerfs périphériques (Malignant peripheral nerve sheath tumor: MPNST) contre 0.001% dans la population générale. A travers deux observations et une revue de la littérature nous discuterons la spécificité de la transformation sarcomateuse au cours de la neurofibromatose de type 1.

No abstract

(6%), 21 (46%), 7 (15%) and 15 (33%) for T1, T2, T3 and T4, respectively. Treatment consisted in a transurethral resection of bladder tumor as complete as feasible followed by curative concurrent chemoradiation. Results:Twenty-nine patients showed complete response (CR), 22 of whom (48%) had a continuously tumor free bladder. With a median follow-up of 30 months (12-92 months), the 3-year overall survival (OS) was 50%; Local recurrence-free survival (LRFS) was 59% at 3 years and the distant metastases free survival (MFS) was

No abstract